PhD cannabinoid psychopharmacology, Institute of Psychiatry, King's College London
Dr Amir Englund has a PhD in Cannabinoid Psychopharmacology and has been involved with several experimental cannabis studies involving healthy volunteers. He has also been involved with clinical trials of cannabidiol (CBD, a non-intoxicating cannabinoid) as a adjunct treatment of patients with a psychotic disorder. He is currently running a study in healthy volunteers where he aims to find the optimum ratio between THC and CBD in cannabis that is least related to cognitive impairment and paranoia.
Speaker at Pulse LIVE Liverpool 2018